Each study has a usefulness score out of 100 (rubric version 4.0). Tap a score to see what makes it up.
Download bibliography of all 5,209 studies, highest score first: BibTeX (.bib) · RIS (.ris)
Highest usefulness score first. Studies without a score come last.
-
The analytic sample included 469 participants (mean age 71.2 ± 8.5 years, 53% female).
Why it matters
This study describes a visual MRI rating of amygdala shrinkage used together with existing Alzheimer's biomarkers to sort memory clinic patients into groups, including one thought to have LATE. It is a retrospective description of patient profiles, not a treatment or cure, and it does not show that this approach changes outcomes.
-
Individuals with rapid progression were more likely to have at least one APOE ε4 allele (OR: 2.08 [95% CI: 1.16–3.74], p < 0.01), higher Braak stage (2.19 [1.20–3.98], p < 0.01), higher Thal phase (2.45 [1.24–4.83], p < 0.01), more severe white matter rarefaction (1.68 [1.21–2.35], p < 0.01), and in the final 24 months of life, more frequent untreated/undertreated hyperlipidemia (1.74 [1.35–5.56], p < 0.01) and less frequent untreated/undertreated depression (0.40 [0.17–0.91], p < 0.05).
Why it matters
Among people with high-level Alzheimer disease neuropathologic change, rapid progression was linked to having at least one APOE ε4 allele and to more severe pathology, while resilient individuals less often carried APOE ε4. The authors suggest resilience and progression may be affected by AD-relevant genetics, pathology severity, and possibly clinical management of underlying systemic disorders.
-
The potential neuroprotective effects of antidiabetic treatments have been largely assessed in Alzheimer's disease (AD) and AD-like dementia models, with or without metabolic disorders.
Why it matters
This systematic review gathered 405 studies on how diabetes drugs, such as GLP-1 receptor agonists, thiazolidinediones, biguanides and insulin, affect Alzheimer's-like changes in animal models and in patients. Overall, the medicines looked promising against neurodegeneration and cognitive decline in preclinical models. The authors note that further research is needed to optimize their clinical effectiveness, so the strongest support so far comes from lab studies.
-
A multivariate analysis was also performed to predict specific risk factors associated with male and female EOAD and LOAD patients.
Why it matters
This cohort study found sex differences in clinical risk factors among patients with early-onset and late-onset Alzheimer's dementia. It identifies associations with comorbidities but does not test a treatment, cure, or prevention.
-
The advent of anti-amyloid monoclonal antibody (mAb) therapies represents a paradigm shift in the treatment of Alzheimer's disease (AD), from symptomatic relief to disease modification.
Why it matters
This practical guide from the Korean Association for Geriatric Psychiatry provides recommendations for the safe use of lecanemab, including candidate selection, ARIA monitoring, and infusion workflows. It is a clinical guidance document and does not itself report new evidence on curing or preventing Alzheimer's disease.
-
Compared with those without CMD, those with CMD multimorbidity had an elevated risk of ACD (hazard ratio [HR]: 2.27, 95% confidence interval [95% CI]: 1.95-2.63), AD (HR: 1.49, 95% CI: 1.13-1.97), and VD (HR: 3.70, 95% CI: 2.93-4.69).
Why it matters
This cohort study found that cardiometabolic multimorbidity was associated with elevated risks of all-cause dementia, Alzheimer's disease, and vascular dementia, with stronger correlations in individuals under 60 or female. It also indicated that neutrophils, glucose, and hemoglobin A1c partially mediated the association with all-cause dementia.
-
Our analysis identified risk factors that contribute to sex differences in ADEN.
Why it matters
This large study found that certain risk factors for encephalopathy in Alzheimer's patients differ between men and women, such as hypertension and traumatic head injury in men and osteoporosis and anxiety in women. It identifies associations only, so it does not show that treating these conditions would prevent or cure Alzheimer's disease.
-
Among 8.5 million hospitalized patients aged 50 years or older, 2,335 had CAA and 600,646 had other CVDs.
Why it matters
In a large cohort of hospitalized patients aged 50 or older, cerebral amyloid angiopathy was associated with about a threefold higher risk of nontraumatic subdural hemorrhage. This identifies CAA as a risk factor for bleeding but does not show how to treat, cure or prevent Alzheimer's disease.
-
Neurodegenerative disorders such as Alzheimer's disease (AD), the most common form of dementia, represent a growing global health crisis, yet current treatment strategies remain primarily palliative.
Why it matters
This review explores how gut bacteria and their metabolites may influence neuroinflammation, blood-brain barrier integrity, and amyloid-beta and tau pathology, and how diets like the Mediterranean diet might modify this. It is a review of existing evidence, not a trial, so it does not establish that any diet prevents or treats Alzheimer's.
-
The GBT model achieved the best AUC-ROC scores of 0.809-0.833 across 1- to 5-year prediction windows.
Why it matters
A machine learning model using electronic health record data predicted Alzheimer's disease and related dementias up to five years in advance with moderate accuracy. It identified both known risk factors like depression and heart disease, and new ones like sleep apnea and headache, which could help personalize screening.
-
Plasma p-tau217 and p-tau231 were most effective in diagnosing aMCI/AD (AUC = 0.95 and 0.93, respectively), while p-tau217, p-tau231 and p-tau181 presented the best differential diagnosis for AD from PSP, FTD and DLB respectively (AUC = 0.84, 0.81 and 0.83). α-synuclein was presented as the best biomarker for PSP variant and behavior variant FTD subtypes (AUC = 0.81 and 0.74, respectively).
Why it matters
This cross-sectional study found that plasma p-tau217 was the most effective blood biomarker for diagnosing Alzheimer's disease and that p-tau markers helped distinguish Alzheimer's from other dementias. It addresses diagnosis, not treatment, cure, or prevention.
-
However, 2023 data indicate that Alzheimer's will likely resume its place as the sixth‐leading cause of death.
Why it matters
This report presents 2025 Alzheimer's disease facts and figures, noting that 2023 data indicate Alzheimer's will likely resume its place as the sixth-leading cause of death, that the number of caregivers has declined while the amount of care provided by each remaining caregiver has increased, and that unpaid caregivers face increased risk for emotional distress and negative mental and physical health outcomes. It also reports survey results that most Americans believe early detection is important and nearly all would want a simple diagnostic test if available, but it does not report results on treating, curing or preventing Alzheimer's disease.
-
56/100
After adjusting for demographics, apolipoprotein E (APOE) ε4 status, cognition, and comorbidities, the highest tertile of REM latency was associated with higher Aβ burden (β = 0.08, 95% confidence interval [CI]: 0.03 to 0.13, p = 0.002), elevated p-tau181 (β = 0.19, 95% CI: 0.02 to 0.13, p = 0.002), and reduced BDNF levels (β = -0.47, 95% CI: -0.68 to -0.13, p = 0.013), compared to the lowest tertile.
Why it matters
Longer REM sleep latency was associated with higher amyloid burden, higher p-tau181, and lower BDNF levels, suggesting it could be a marker or risk factor for Alzheimer's and related dementias. The authors state that a trial is needed to find out whether targeting REM latency can change dementia risk.
-
Among 4080 participants included in the analysis, the mean (SD) age was 66.5 (8.9) years, and 2241 (54.9%) were female.
Why it matters
In this cross-sectional study of 4,080 participants, amyloid pathology and APOE ε4 copy number were associated with increased odds of lobar cerebral microbleeds in cognitively unimpaired people. In those with mild cognitive impairment or Alzheimer dementia, amyloid pathology was associated with presence of any cerebral microbleeds.
-
The rising age of the global population has made Alzheimer's disease and related dementias (ADRD) a critical public health problem, with significant health-related disparities observed between rural and urban areas.
Why it matters
This scoping review notes that Alzheimer's disease and related dementias are a critical public health problem with significant health-related disparities between rural and urban areas. It describes disparities only and does not test any treatment, cure, or prevention.
-
For both cohorts, the prevalence of mosaicism was 40 and Aβ 42 concentrations.
Why it matters
In an older cohort, adults with Down syndrome who had mosaicism showed less cognitive decline and lower incidence and prevalence of dementia than those with full trisomy. Mosaicism was also linked to lower plasma amyloid peptide concentrations, possibly lowering Alzheimer's risk, but the clinical impact was less clear in the younger cohort and follow-up is needed.
-
Alzheimer's disease (AD) presents a significant challenge in neurodegenerative research and clinical practice due to its complex etiology and progressive nature.
Why it matters
This review describes how AI could help detect Alzheimer's earlier through imaging and biomarker analysis, and could help match treatments to individual patients. It does not report new trial results, so it does not yet show that AI changes outcomes for patients.
-
It remains unknown whether the associations between protective lifestyles and sporadic dementia risk reported in observational studies also affect age at symptom onset (AAO) in autosomal dominant Alzheimer disease (ADAD) with predominant genetic influences.
Why it matters
This longitudinal analysis of the Dominantly Inherited Alzheimer Network cohort examined whether resilience-related life experiences relate to variability in age at symptom onset in autosomal dominant Alzheimer's disease. It reports associations with onset timing and does not show that any experience treats, cures or prevents the disease.
-
The findings underscore the potential of integrating physical exercise into comprehensive AD management strategies.
Why it matters
Drawing on recent studies, this review reports that regular physical exercise alters inflammation pathways in the brain in people with Alzheimer's, including the activity of microglia and astrocytes, the brain's support and immune cells, and strengthens the blood-brain barrier. These changes were associated with better thinking and brain health. The authors support adding exercise to Alzheimer's care while calling for more research to refine exercise programs.
-
NE3107 was associated with clinician-rated improvements in cerebral blood flow and functional connectivity within the brain.
Why it matters
In a phase 2, open-label study, 23 people with mild cognitive impairment or mild dementia took NE3107, an oral anti-inflammatory drug, twice daily for 3 months. It was associated with clinician-rated improvements in brain blood flow and, in the 17 patients with milder disease, statistically significant gains on several cognitive and dementia rating scales. Because the study was open-label, meaning everyone knew they were getting the drug, these are early signals rather than proof that it works.
-
Alzheimer's disease (AD) pathology is defined by β-amyloid (Aβ) plaques and neurofibrillary tau, but Lewy bodies (LBs; 𝛼-synuclein aggregates) are a common co-pathology for which effective biomarkers are needed.
Why it matters
In spinal-fluid samples from 1,638 participants in the Alzheimer's Disease Neuroimaging Initiative, an α-synuclein seed amplification test flagged Lewy body co-pathology. Against autopsy in 78 people, it showed 79% sensitivity and 97% specificity: it caught all neocortical cases (100%) but only 57% of limbic and 60% of amygdala-predominant cases. Overall, 22% of participants tested positive, a rate that rose with disease stage and age. This is a diagnostic association study, not evidence about treatment or prevention.
-
Midlife NAFLD shows associations with AD and accumulating vascular pathology, revealing potential pathways linking liver function to dementia.
Why it matters
Midlife nonalcoholic fatty liver disease was linked to greater late-life white matter hyperintensity volume and to some Alzheimer-related plasma biomarker changes. This is about possible risk factors and mechanisms, not about treating, curing, or preventing Alzheimer's disease.
-
Disease staging, whereby the spatial extent and load of brain pathology are used to estimate the severity of Alzheimer disease (AD), is pivotal to the gold-standard neuropathological diagnosis of AD.
Why it matters
This review discusses staging Alzheimer's disease using biomarkers such as amyloid and tau, and how staging could refine trial enrollment and clinical decisions in the era of anti-amyloid therapies. It is about staging and diagnosis, not about a treatment, cure, or prevention.
-
The sensitivity of amyloid to pre-analytic factors complicates cerebrospinal fluid (CSF) diagnostics for Alzheimer disease.
Why it matters
This study examined how handling and storage of spinal fluid samples affect the reliability of Alzheimer's biomarker measurements. It is about laboratory methods and quality control, not about treating or preventing the disease.
-
The early diagnosis of Alzheimer's disease (AD) presents a significant challenge due to the subtle biomarker changes often overlooked.
Why it matters
This study used machine learning on a large dataset to classify Alzheimer's disease and predict its progression over 4 years, with support vector machine models showing high performance. The authors also generated human-understandable rules to help experts understand the key factors involved in classification.
From across this topic
10 of the 5,172 studies in this topic, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
- Serial MRI and CSF biomarkers in normal aging, MCI, and AD
- Ultrasound Neuromodulation With Transcranial Pulse Stimulation in Alzheimer Disease: A Randomized Clinical Trial
- Overcoming the blood–brain barrier in Alzheimer's disease: translational perspectives on advanced drug delivery platforms
- Amyloid-first and neurodegeneration-first profiles characterize incident amyloid PET positivity
- SPECT and PET imaging in Alzheimer's disease
- Methodological Considerations for Quantile Aggregation in Alzheimer Disease Trials
- Update on appropriate use criteria for amyloid PET imaging: dementia experts, mild cognitive impairment, and education
- Exercise alters the immune profile in Tg2576 Alzheimer mice toward a response coincident with improved cognitive performance and decreased amyloid
- Utilizing semantic intrusions to identify amyloid positivity in mild cognitive impairment
- Combined Plasma and Cerebrospinal Fluid Signature for the Prediction of Midterm Progression From Mild Cognitive Impairment to Alzheimer Disease